We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare ...

Biogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies for inherited retinal disorders, in a deal worth $800 million. The US biotech ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug has been recommended by the European Medicines Agency’s human medicines ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here.

The drug was deemed too expensive for the UK's state-run health service in August. The EU regulator is expected to wrap up reexamining the drug's rejection this year, Biogen said. Leqembi is also ...